Loxo Oncology Profile

USD 2.24  1.25%

Sale by Joshua Bilenker of 1100 shares of Loxo Oncology

Loxo Oncology insider trading alert for sale of common stock by Joshua Bilenker, President & CEO, on June 13, 2018. This event was filed by Loxo Oncology Inc with SEC on 2018-03-15. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Loxo Oncology Summary

Loxo Oncology (LOXO) is traded on NASDAQ General Markets in USA. It is located in CONNECTICUT, U.S.A and employs 73 people. Loxo Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 5.32 B. Loxo Oncology conducts business under Healthcare sector and is part of Biotechnology industry. This company has 30.08 M outstanding shares of which 3.59 M shares are now shorted by private and institutional investors with about 10.53 trading days to cover. Loxo Oncology currently holds about 710.23 M in cash with 244.21 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61.
Check Loxo Oncology Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 176.93HorizonTargetOdds Above 176.93
61.70%30 days 176.93 37.99%
Based on normal probability distribution, the odds of Loxo Oncology to move above current price in 30 days from now is about 37.99% (This Loxo Oncology probability density function shows the probability of Loxo Oncology Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares4.3 M500.1 M
Aisling Capital LlcCommon Shares3.4 M396.7 M
View Loxo Oncology Diagnostics

Selected Loxo Oncology Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Loxo Oncology Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Loxo Oncology are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 73 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameLoxo Oncology
President CEO, DirectorJoshua BilenkerView All
Thematic Classifications
Active Investing Ideas
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address281 Tresser Boulevard
ExchangeNASDAQ General Markets
CIK Number01581720.0
Contact Number203 653 3880
CurrencyUSD - US Dollar


Loxo Oncology Analyst Recommendations
Target PriceAdvice# of Analysts
50.33Strong Buy3Odds
Loxo Oncology current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Loxo Oncology Analyst Advice  


Loxo Oncology Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.86March 21, 2017
Loxo Oncology normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Loxo Oncology Corporate Directors
James Barrett Independent Director, MBA
Timothy Mayleben Independent Director, MBA
Avraham Naider Independent Director
Please see also Stocks Correlation. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.